Delphia Therapeutics, a Cambridge, MA-based biotechnology company which specializes in cancer therapeutics, raised $67M in Series A funding.
The round was led by GV, Nextech Invest, Polaris Innovation Fund and Alexandria Venture Investments.
The company intends to sue the funds to expand operations and its R&D sector.
Delphia Therapeutics is leveraging its activation lethality platform to develop highly differentiated, first-in-class targeted cancer medicines with the potential for significant anti-tumor activity and more durable patient benefit. The company integrates tumor genetics, novel functional genomic approaches, and studies of inhibitor drug resistance to identify targets that drive activation lethality.
Co-founders include:
- Bill Sellers, M.D., director of the cancer program of the Broad Institute of MIT and Harvard
- Mike Dillon, Ph.D., former chief scientific officer of IDEAYA Biosciences and former global head of discovery chemistry for oncology at Novartis Institutes for BioMedical Research (NIBR)
- Kevin Marks, Ph.D., president and CEO of Delphia, entrepreneur-in-residence at GV, and former oncology drug discovery site head at NIBR
